Abstract. Familial hypercholesterolemia (FH) is a genetic disorder characterized by a high serum concentration of low-density lipoprotein (LDL) cholesterol. The high LDL cholesterol level leads to an excess deposition of cholesterol in the arterial walls and accelerated atherosclerosis, thereby increasing the risk of premature coronary heart disease. In the present study, we used a DNA microarray approach to identify gene expression profiles that distinguish patients with FH from healthy control subjects. Furthermore, transcription factors (TFs), microRNAs (miRNAs), target genes and pathways were analyzed to explore the potential transcriptional interactions occurring in FH. Publicly available microarray and regulation data were used to construct a regulatory network to identify additional genes related to FH and their interactions. The results revealed that specificity protein 1 (SP1), signal transducer and activator of transcription 1 (STAT1) and spleen focus forming virus (SFFV) proviral integration oncogene spi1 (SPI1) play a central role in the FH regulatory network. In addition, the TF, upstream transcription factor 2, c-fos interacting (USF2) and the gene, Wiskott-Aldrich syndrome (WAS), were identified to be associated with FH, although no reports for these proteins exist in the literature. Overall, transcriptional network analysis proved to be effective approach to identify novel targets for FH therapy.
Introduction
Familial hypercholesterolemia (FH) is a genetic disorder characterized by a high serum concentration of low-density lipoprotein (LDL) cholesterol. The high LDL cholesterol level accelerates the deposition of cholesterol in the arterial walls and leads to atherosclerosis, thereby increasing the risk of premature coronary heart disease (1) .
The most common genetic defects underlying FH are mutations in the LDL receptor (LDLR), the apolipoprotein B (ApoB)-100 and the pro-protein convertase subtilisin/kexin type 9 (PCSK9) genes (2) . LDL cholesterol normally circulates in the body for 2.5 days, and subsequently binds to LDLR on liver cells, undergoes endocytosis and is then digested. LDL is removed, and the synthesis of cholesterol by the liver is suppressed by the HMG-CoA reductase pathway. In FH, the function of LDLR is reduced or absent, and LDL circulates for an average duration of 4.5 days, resulting in a significantly increased level of LDL cholesterol in the blood, while other lipoproteins show normal levels (3) . In patients with ApoB mutations, the reduced binding of LDL particles to the receptor causes an increased level of LDL cholesterol (4) . The expression of PCSK9 normally downregulates the LDLR pathway by indirectly inducing the degradation of the LDLR protein, and loss-of-function mutations in PCSK9 result in low plasma LDL levels. Thus, PCSK9 is an attractive target for the development of novel drugs aiming to reduce the serum LDL cholesterol level (5) .
DNA microarray analysis is a high-throughput approach that allows the comparison of transcriptional profiles between healthy and diseased individuals or samples, among other applications (6) . DNA microarray analysis has been previously used to analyze gene expression patterns and to identify differentially expressed genes in FH (7) .
In this study, we used a similar strategy to identify gene expression profiles that distinguish patients with FH from healthy control subjects. Furthermore, data on the relevant transcription factors (TFs), microRNAs (miRNAs), target genes and pathways were analyzed so as to construct an FH regulatory network and to explore the potential molecular interactions involved in the development of FH.
Materials and methods

Data resources
Affymetrix microarray data. The transcription profiles of patients with ischemic cardiomyopathy (8) were obtained from the study with Accession no. GSE6054 deposited at the GEO Regulation data. There are approximately 2,600 proteins in the human genome that contain DNA-binding domains, and most of these are presumed to function as TFs (10) . The combined use of a subset of approximately 2,000 human TFs easily accounts for the unique regulation of each gene in the human genome during development (11) . These TFs are grouped into 5 superfamilies, based on the presence of conserved DNA-binding domains. The TRANScription FACtor database (TRANSFAC) contains data on TFs, their experimentally proven binding sites, and regulated genes (12) . The Transcriptional Regulatory Element Database (TRED) has been built in response to increasing needs for an integrated repository for both cis-and trans-regulatory elements in mammals (13) . TRED contains curated information on transcriptional regulation, including experimentally verified TF binding motifs. We collected 774 pairs of regulatory interactions between 219 TFs and 265 target genes from TRANSFAC and 5,722 pairs of regulatory interactions between 102 TFs and 2,920 target genes from TRED. By combining the two datasets, a total of 6,328 regulatory interactions between 276 TFs and 3,002 target genes were collected (Table I) .
miRNA datasets. We integrated disease-associated miRNA datasets with datasets of miRNAs and target genes to explore the association between miRNA-regulated genes and diseases. The human miRNA disease database (HMDD) (14) , a resource of curated information on the associations of miRNAs and disease as supported by experimental evidence, contains 444 miRNA genes, 259 diseases, 1,149 publications and 2,886 miRNA-disease associations. miR2Disease (15) provides a comprehensive resource of miRNA deregulation in various human diseases. A total of 349 miRNAs and 163 diseases were collected from this database. The above 2 databases were merged, resulting in 5,036 associations of miRNAs with diseases. We also integrated experimentally supported data on miRNA target genes from starBase (16), miRecords (17) and TarBase (18) . Overall, 211,464 associations between miRNA and target genes were selected.
Methods
Differentially expressed gene (DEG) analysis.
For the GSE6054 dataset, the limma method (19) was used to identify DEGs. The raw expression data from all conditions were normalized using the RMA method implemented in Bioconductor (20) with default settings, and then a linear model was applied. DEGs were defined as genes showing a fold change value >1.5 and a corrected p-value <0.05.
Co-expression analysis. To demonstrate the potential regulatory association between TFs and DEGs, Pearson's correlation coefficient (PCC) was calculated for all pair-wise comparisons of gene expression values between the TFs and DEG. The regulatory association was considered significant at PCC>0.6 or PCC <-0.6.
Gene Ontology (GO) analysis. DAVID (21), a highthroughput and integrated data-mining environment, analyzes gene lists derived from transcriptomic comparisons. We used DAVID to identify categories of biological processes (as defined in the GO annotation system) that were overrepresented in our dataset, by applying a threshold p-value <0.01.
Construction of regulatlory network between genes and TFs. Using the regulation data from TRANSFAC and TRED, we matched differentially expressed TFs to their predicted target genes. Based on this, and information on the interactions between genes in the pathways they belong to, we constructed regulatory networks using Cytoscape (22) . Regulatory associations between TFs and genes were verified based on co-expression analysis.
Pathway significance analysis. We adopted an impact approach that calculates the statistical significance of a set of genes belonging to a certain pathway, but also considers other factors, such as the magnitude of change in expression of each gene, the topology of the related pathway and interactions between the genes (23) . In this model, the impact factor (IF) of a pathway P i is calculated as the sum of 2 terms (equation 1) as follows:
The first term is a probabilistic term that captures the significance of the given pathway P i from the perspective of the set of genes in the pathway. It is obtained by using a hyper- geometric model in which p i is the probability of obtaining at least the observed number of DEGs, N de by chance (24, 25) . The second term is a functional term, that depends on the identity of the specific genes that are differentially expressed, as well as on the interactions described by the pathway (i.e., its topology). The second term sums up the absolute values of the perturbation factor (PF) for all genes 'g' on the given pathway P i . The PF of a gene 'g' is calculated (equation 2) as follows:
In this equation, the term ΔE (g) captures the quantitative information measured in the gene expression experiment. The factor ΔE (g) represents the normalized measured expression change of the gene 'g'. The second term is the sum of all PFs of the genes 'u' directly upstream of the target gene 'g' PF(u), normalized by the number of downstream genes for each such gene N ds (u), and weighted by a factor β ug , which reflects the type of interaction: β ug = 1 for induction and β ug = -1 for repression (KEGG supplies this information in the description of the pathway topology). US g is the set of all genes upstream of 'g'. In equation 1, we normalized for the size of the pathway by dividing the total perturbation by the number of DEGs in the given pathway, N de (P i ). In order to make the IF calculation as independent as possible from the technology and also comparable between studies (23), we also divided the second term in equation 1 by the mean absolute fold change ΔE, calculated across all DEGs. The results from the pathway significance analysis are presented in Table II .
Construction of a regulatory network between TFs and pathways. To further investigate the regulatory association between TFs and different pathways, we mapped DEGs to pathways and constructed a regulatory network describing the associations between the TFs predicted to regulate these genes and pathways.
miRNA network construction. From the miRNA-disease data collected from the HMDD and miR2Disease databases, we focused on those concerning esophageal diseases. The esophageal disease-related miRNAs were then mapped to their predicted target genes. In total, 14 miRNAs and 431 DEGs were used to construct the network.
Results
Regulatory network in FH.
To obtain a list of genes differentially expressed in FH, we downloaded raw data from the publicly available microarray dataset, GSE6054, from the GEO repository. Following data normalization, 443 DEGs were identified based on a fold change value threshold >1.5 and a p-value threshold <0.05. To obtain the regulatory associations between these DEGs and TFs, we applied a PCC threshold >0.6 in the co-expression analysis. In total, 12 regulatory associations were identified, involving 8 TFs and 8 differentially expressed target genes. The resulting regulatory network describing FH is presented in Fig. 1 . In this network, specificity protein 1 (SP1), signal transducer and activator of transcription 1 (STAT1) and spleen focus forming virus (SFFV) proviral integration oncogene spi1 (SPI1) formed local networks with a higher node degree, which suggests that these genes play important roles in FH. STAT1 activates 3 target genes, interferon induced transmembrane protein 1 (IFITM1), interferon-induced protein with tetratricopeptide repeats 2 (IFIT2) and interferon, α-inducible protein 6 (IFI6). SP1, regulated by upstream transcription factor 2, c-fos interacting (USF2), activates integrin, beta 1 (ITGB1), while the Wiskott-Aldrich syndrome (WAS) gene is regulated by both transcription factors, SPI1 and v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) (ETS1).
GO analysis of the regulatory network in FH.
Several GO categories were enriched among the 16 genes in the regulatory network. These included biological processes (BP) such as positive regulation of gene expression, positive regulation of transcription, DNA-dependent positive regulation of RNA metabolic process etc. (Table III lists the top 10 enriched BP categories).
Pathways involved in FH.
To identify the pathways that are the most affected by FH, we used a statistical approach at the pathway level. Significance analysis at the single gene level may suffer from the limited number of samples and from experimental noise, which can severely limit the power of the selected statistical test. Pathway analysis allows the application of a more relaxed significance threshold than the one applied to single genes, while still leading to better biological interpretations. Therefore, we adopted a pathwaybased impact analysis method that considered a number of factors, including the statistical significance of changes in the expression of DEGs that are assigned to a certain pathway, the magnitude of change in expression of each gene, the topology of the pathway, and the predicted regulatory interactions among genes. The impact analysis revealed a number of pathways deemed relevant to FH, such as long-term depression, gap junction and long-term potentiation (Table II) .
Regulatory network of TFs and pathways.
To further investigate the regulatory associations between TFs and pathways, we assigned DEGs to the relevant pathways and obtained a regulatory network between TFs regulating these DEGs (based on the co-expression analysis results) and pathways (Fig. 2) . In this network, SP1, USF2 and STAT4 were identified as hub nodes linked to a high number of FH-related pathways. For example, STAT4 activates type I diabetes mellitus, STAT1 activates the B cell receptor signaling pathway, while among pathways regulated by SP1 were those related to focal adhesion and axon guidance.
miRNA network in FH. Using the miRNA-disease data collected from the HMDD and miR2Disease databases, we matched the genes previously identified as part of the FH regulation nework to data describing the miRNA-target gene associations. The FH-related miRNAs were selected and mapped to disease-miRNA data. A total of 132 miRNAs and 16 genes were used to construct the network. The final miRNA network includes five genes associated with 37 miRNAs with node degrees >2 (Fig. 3) .
Discussion
The present analysis allowed the identification of a number of TFs and pathways associated with FH. Among these, SP1, STAT1 and SPI1 formed a local network, which suggests that these genes play important roles in FH. In addition, SP1, USF2 and STAT4 appeared as hub nodes in the TFs-pathways network. We discuss below the association between FH and the genes identified herein based on the current literature. SP1, a human transcription factor, contains a zinc finger protein motif, by which it binds directly to DNA and enhances STAT1 is a member of the STAT protein family. This protein can be activated by various ligands, including interferon (IFN)-α, IFN-γ, epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and IL-6, to function as a transcriptional activator. Analysis of monocytes from patients with FH revealed that a significant number of these have elevated STAT1 levels, as a result of activation by IFN-γ (30) .
The ITGB1 gene encodes a β subunit of integrins. Integrin family members are membrane receptors involved in cell adhesion and recognition in a variety of processes. Monocyte activation and migration into the arterial wall, with subsequent differentiation into macrophages, are key events in atherogenesis associated with FH. ITGB1 has been found to be highly expressed during monocyte to macrophage differentiation and differentially expressed in CD16 -and CD16 + monocytes, indicating a later stage of maturation of CD16 + monocytes from FH homozygotes compared with monocytes from healthy individuals (31) . This protein may play an important role in monocyte adhesion and the development of atherosclerosis, thereby representing a potentially novel therapeutic target for atherosclerosis (32) .
Autopsy studies in children have shown that atherosclerotic lesions begin to develop first in the intima of the aorta. Therefore, a previous study examined the feasibility of measuring intimamedial thickness of the abdominal aorta (aIMT) in children and studied its value in distinguishing high-risk children from healthy controls as compared to a more established marker of subclinical atherosclerosis, the common carotid artery intimamedial thickness (cIMT). The results indicated that children with FH and type 1 diabetes show increased IMT compared with healthy controls, with a relatively greater increase in aIMT than in cIMT. These data suggested that aIMT may provide the best currently available noninvasive marker of preclinical atherosclerosis and type 1 diabetes in children (33) .
A number of studies have indicated that T and B cells exert a pro-atherogenic effect in FH. Cell-mediated immune responses by macrophages and T lymphocytes occur in atherosclerotic lesions. These are to a large extent caused by specific CD4 + T cells responding to oxidized LDK (ox-LDL) (34) . Ox-LDL is an important local antigen in atherosclerosis and recognized by antigen receptors, such as T cell receptors (TCRs). Such local T cell responses may activate B cells through B cell receptors (BCRs), with concomitant systemic antibody production (35) .
In conclusion, we used network analysis as an exploratory framework to study the pathobiology of FH, based on the assumption that FH is a contextual attribute of distinct interaction patterns among multiple genes. The most notable results of our study include the identification of FH-related TFs, target genes and pathways such as SP1, SPI1, STAT1, ITGB1, focal adhesion pathway, type I diabetes mellitus pathway and B cell receptor signaling pathway. In addition, our results indicated that USF2 and WAS might play an important role in FH, although no relevant report for this finding exists in the literature. Therefore, future studies are required to confirm our results.
